...
首页> 外文期刊>Applied immunohistochemistry and molecular morphology: AIMM >Tissue microarray technique in soft tissue sarcoma: immunohistochemical Ki-67 expression in malignant fibrous histiocytoma.
【24h】

Tissue microarray technique in soft tissue sarcoma: immunohistochemical Ki-67 expression in malignant fibrous histiocytoma.

机译:软组织肉瘤中的组织芯片技术:恶性纤维组织细胞瘤中免疫组化Ki-67表达。

获取原文
获取原文并翻译 | 示例
           

摘要

Malignant fibrous histiocytoma (MFH) represents a heterogeneous soft tissue sarcoma entity. The authors compared different methods to determine immunohistochemical staining in whole tissue sections, evaluated the tissue microarray technique, and assessed immunohistochemical heterogeneity using the proliferation marker Ki-67 in 47 histopathologic tumor blocks from 11 MFHs. Whole tissue sections were assessed counting 400 cells along a line and counting all cells in 10 high-power fields (0.16 mm2) with mean Ki-67 expression levels of 13% and 11%, respectively. For the tissue microarray technique, two to three 0.6-mm diameter biopsies were studied from each of the 47 tumor blocks. Good correlation was obtained between whole tissue immunohistochemistry and tissue microarray with the microarray method, giving on average 8.6% greater Ki-67 expression levels than the reference method. Immunohistochemical tumor heterogeneity, evaluated using the high-power field method, showed a median standard deviation of 2.3% within the tumor blocks and 2.5% between the blocks from the same tumor. The authors concluded that the tissue microarray technique yields good quality staining and expression levels for Ki-67 comparable with whole tissue methods in MFH, but because of tumor heterogeneity, several tumor blocks ideally should be studied and, because of loss of material in the microarray process, multiple biopsies should be taken. The feasibility of tissue microarray for immunohistochemical studies of soft tissue sarcomas offers new possibilities to study multiple markers in large tumor materials.
机译:恶性纤维组织细胞瘤(MFH)代表异质性软组织肉瘤实体。作者比较了确定整个组织切片中免疫组织化学染色的不同方法,评估了组织微阵列技术,并使用增殖标记物Ki-67在来自11个MFH的47个组织病理学肿瘤块中评估了免疫组织化学异质性。评估整个组织切片,沿一条线计数400个细胞,并计数10个高倍视野(0.16 mm2)中的所有细胞,平均Ki-67表达水平分别为13%和11%。对于组织微阵列技术,从47个肿瘤块中的每个进行了2到3个直径为0.6 mm的活检。用微阵列方法在全组织免疫组织化学和组织微阵列之间获得了良好的相关性,平均给出了Ki-67表达水平比参考方法高8.6%。使用高功率场法评估的免疫组织化学肿瘤异质性显示,在同一肿瘤块内,肿瘤块内的中位标准差为2.3%,在两个肿​​瘤块之间的中位标准差为2.5%。作者得出的结论是,组织微阵列技术可产生与MFH中的全组织方法相当的高质量Ki-67染色和表达水平,但由于肿瘤异质性,理想地应研究几个肿瘤块,并且由于微阵列中材料的损失在此过程中,应进行多次活检。组织芯片用于软组织肉瘤免疫组织化学研究的可行性为研究大型肿瘤材料中的多种标记物提供了新的可能性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号